2805 T3D2763 Anidulafungin Anidulafungin is a solid, exogenous compound with the formula C58H73N7O17. Anidulafungin belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. With an average molecular weight of 1,140 g/mol, Anidulafungin is a heavy molecule. It functions as an antibiotic and antifungal agent. It is found in antimycotics within healthcare, pharmaceuticals, and veterinary products, as well as in other smoking requisites and non-electric simulated smoking devices within household cleaning and consumer products. The recorded route of exposure for this compound is intravenous. As a semi-synthetic echinocandin, anidulafungin exhibits antifungal activity by inhibiting glucan synthase. Because this enzyme is present in fungal cells but not mammalian cells, the compound inhibits the formation of 1,3-β-D-glucan, which is an essential component of the fungal cell wall. Additionally, anidulafungin acts as an inhibitor of Cytochrome P450 1A2 (CYP1A2), Cytochrome P450 2D6 (CYP2D6), Cytochrome P450 2C9 (CYP2C9), and Cytochrome P450 2B6 (CYP2B6), along with three other proteins. 166663-25-8 166548 C58H73N7O17 1139.506290 White powder. Practically insoluble Injection Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-&beta;-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death. During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. Route of Elimination: Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized. Half Life: 40-50 hours During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). No indication of carcinogenicity to humans (not listed by IARC). For use in the treatment of the following fungal infections: Candidemia and other forms of <i>Candida</i> infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis. Possible side effects include allergic reaction; bronchospasm; fever, chills, body aches, flu symptoms, sores in mouth and throat; nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); low potassium; hot flashes; diarrhea or constipation; nausea, vomiting. (L1712) During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). 2009-07-21T20:26:41Z 2026-08-22T19:38:52Z Anidulafungin 55346 Anidulafungin DB00362 true [H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O C58H73N7O17 InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 1140.2369 1139.506293945 Exogenous Solid 2.9 HMDB14506 CHEMBL264241 145752 <p>Scott Jenkins, Gary Liversidge, Deborah Neville, &#8220;Nanoparticulate Anidulafungin Compositions and Methods for Making the Same.&#8221; U.S. Patent US20090238867, issued September 24, 2009.</p> CHEM002180 DTXSID50873201 NS00007722 N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide 377.41999999999985 292.29319999999984 122.37763185616006 14 17 14 9.457179266012721 -3.484584020108345 0 7 1.87 -4.31 5.64e-02 g/l Organic compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues 1403 CED0004099 JHVAMHSQVVQIOT-MFAJLEFUSA-N 4404100000000000000080000200008008000000000002000000000810000000000000300204002020000000000000001000000000000000000000000200000000000000000000000003000000040000002000000009010000020000104000000000002009000810000044000000020080000002010000000000140000000012002000004000000000000020000000008080000000000000000000004040000008080004c020000000800400084000000000000008080000000100002008004001400000000000002000080008000000400000004000000000000200000020002000000001000004100040000000010400000000018800080000800004000000 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 776t3gAAAAAQAAAAAwAAAAAAAABSAAAAWAAAAIABBiA0AAAAAgEEBgBgAAAA AgIGIDQAAAABAQQIAGAAAAABAQYAYAAAAAICBwAoAAAAAwMGACgAAAADBAgA KAAAAAMCBiA0AAAAAQEEBwBoAAAAAwIBBgAoAAAAAwQIACgAAAADAgYgNAAA AAIBBAYAYAAAAAICBiA0AAAAAQEECABgAAAAAQEGIDQAAAABAQQIAGAAAAAB AQcAaAAAAAMCAQYAKAAAAAMECAAoAAAAAwIGIDQAAAACAQQGIDQAAAABAQQI AGAAAAABAQYgNAAAAAEBBAYAYAAAAAEDBgBgAAAAAgIHACgAAAADAwYAKAAA AAMECAAoAAAAAwIGIDQAAAABAQQHAGgAAAADAgEGACgAAAADBAgAKAAAAAMC BiA0AAAAAQEEBwBoAAAAAwIBBgAoAAAAAwQIACgAAAADAgYgNAAAAAIBBAgA YAAAAAEBBiA0AAAAAQEECABgAAAAAQEGQCgAAAADBAZAaAAAAAMDAQZAaAAA AAMDAQZAKAAAAAMECABoAAAAAwEBBkBoAAAAAwMBBkBoAAAAAwMBBiA0AAAA AQEEBgBgAAAAAQMIAGAAAAABAQcAaAAAAAMCAQYAKAAAAAMECAAoAAAAAwIG QCgAAAADBAZAaAAAAAMDAQZAaAAAAAMDAQZAKAAAAAMEBkBoAAAAAwMBBkBo AAAAAwMBBkAoAAAAAwQGQGgAAAADAwEGQGgAAAADAwEGQCgAAAADBAZAaAAA AAMDAQZAaAAAAAMDAQZAKAAAAAMEBkBoAAAAAwMBBkBoAAAAAwMBBkAoAAAA AwQIACgAAAADAgYAYAAAAAICBgBgAAAAAgIGAGAAAAACAgYAYAAAAAICBgBg AAAAAQMGQGgAAAADAwEGQGgAAAADAwEGIDQAAAABAQQGAGAAAAABAwgAYAAA AAEBCwABAAECAAIDAAIEAAQFAAUGIAYHKAIGCAAICQAJCiAKCygCCgwADA0A DQ4ADg8ADhAAEBEAEBIAEhMgExQoAhMVABUWABYXABYYABgZABgaABobABsc IBwdKAIcHgAeHwAfICAgISgCICIAIiMAIyQgJCUoAiImACYnACYoACgpACgq ACoraAwrLGgMLC1oDC0uIC0vaAwvMGgMHjEAMTIAMTMADDQANDUgNTYoAjU3 IDc4aAw4OWgMOTpoDDo7aAw7PGgMOj0gPT5oDD4/aAw/QGgMQEFoDEFCaAxA QyBDRGgMREVoDEVGaAxGRyBHSABISQBJSgBKSwBLTABGTWgMTU5oDAhPAE9Q AE9RAAUAABsVADAqaAw8N2gMQj1oDE5DaAwkAABCBwAAAAUBAAUEAhUGBQAk IyIgHx4cGxUTEhAODQwKCQgFFhUbGhgGKywtLzAqBjg5Ojs8NwY+P0BBQj0G REVGTU5DFwQAAAAAAAAAFg== 2026-09-19T04:00:33Z